

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Mikhail Karim</u> (Last) (First) (Middle) <u>C/O AMARIN PHARMA, INC.</u> <u>440 US HIGHWAY 22</u> (Street) <u>BRIDGEWATER NJ 08807</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>08/10/2021</u>	3. Issuer Name and Ticker or Trading Symbol <u>AMARIN CORP PLC\UK [AMRN]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p align="center"><u>President & CEO</u></p>	5. If Amendment, Date of Original Filed (Month/Day/Year)
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Ordinary Shares⁽¹⁾</u>	<u>23,540</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Stock Option (Right to Buy)</u>	<u>(2)</u>	<u>07/01/2030</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>100,000</u>	<u>7.03</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(3)</u>	<u>01/04/2031</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>46,000</u>	<u>5.03</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(4)</u>	<u>04/12/2031</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>290,200</u>	<u>4.97</u>	<u>D</u>	
<u>Restricted Stock Units⁽⁵⁾</u>	<u>(6)</u>	<u>(7)</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>66,666</u>	<u>0.00</u>	<u>D</u>	
<u>Restricted Stock Units⁽⁵⁾</u>	<u>(8)</u>	<u>(7)</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>34,100</u>	<u>0.00</u>	<u>D</u>	
<u>Restricted Stock Units⁽⁵⁾</u>	<u>(9)</u>	<u>(7)</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>215,200</u>	<u>0.00</u>	<u>D</u>	

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. On July 1, 2020, the Reporting Person was granted an option to purchase 100,000 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "2011 Plan"). The shares subject to this option shall vest and become exercisable over four years, with 25% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 12 calendar quarters on the first day of each October, January, April and July.

3. On January 4, 2021, the Reporting Person was granted an option to purchase 46,000 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "2020 Plan"). The shares subject to this option shall vest and become exercisable over four years, with 25% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 12 calendar quarters on the last day of each March, June, September and December.

4. On April 12, 2021, the Reporting Person was granted an option to purchase 290,200 Ordinary Shares under the 2020 Plan. The shares subject to this option shall vest and become exercisable over four years, with 25% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 12 calendar quarters on the twelfth (12th) day of each July, October, January and April.

5. Each restricted stock unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.

6. On July 1, 2020, the Reporting Person was granted 100,000 RSUs under the 2011 Plan. These RSUs vest in three equal installments on each of July 1, 2021, July 1, 2022 and July 1, 2023.

7. Not applicable.

8. On January 4, 2021, the Reporting Person was granted 34,100 RSUs under the 2020 Plan. These RSUs vest in three equal installments on each of December 31, 2021, December 31, 2022 and December 31, 2023.

9. On April 12, 2021, the Reporting Person was granted 215,200 RSUs under the 2020 Plan. These RSUs vest in three equal installments on each of April 12, 2022, April 12, 2023 and April 12, 2024.

Remarks:

Karim Mikhail

08/10/2021

** Signature of Reporting
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.